Project Grant R01HL187976
Award Date 9/1/26
Completion Date 5/31/31
Dollars Obligated $677K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded $1.775 million to Boston Children's Hospital on September 1, 2026, to investigate pericyte-to-smooth-muscle-cell transitions in pulmonary arterial hypertension, under the Cardiovascular Diseases Research program (CFDA 93.837). The research addresses excessive vascular remodeling in pulmonary arterial hypertension by examining how pericytes—specialized mural cells that maintain capillary stability—transition into smooth muscle-like cells under...
- This $428,220 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by the University of Colorado-Denver to provide "Innovative Insights into Pulmonary Hypertension Progression: Unraveling the Role of Localized Small Extracellular Vesicles." The research, conducted from December 1, 2024 through November 30, 2026, aims to advance the scientific understanding of pulmonary hypertension and...
- The National Heart Lung and Blood Institute awarded The Regents Of The University Of Colorado, doing business as University Of Colorado-Denver, $786,950 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to conduct Project Grant R01HL184900, investigating mitochondrial uncoupling protein-2 (UCP2) as a metabolic regulator of fibroblast activation in idiopathic pulmonary fibrosis (IPF). The research defines UCP2's transport function and its role in sustaining...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of Colorado (University of Colorado-Denver) $746,392 in project grant funding on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to delineate ventilator-induced lung injury arising from specific types of ventilator dyssynchrony—double-triggered, flow-limited, and ineffective-triggered breaths. The research addresses the gap in understanding dose-response relationships between...
- The National Heart, Lung, and Blood Institute awarded Medluidics LLC $227,639 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a cardiopulmonary unit-on-a-chip for investigating right ventricular hypertrophy caused by pulmonary arterial hypertension and for developing targeted treatments. The recipient will develop a microfluidic device that models both the right ventricle and pulmonary artery separated by a collagen layer, enabling culture of...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of Colorado, doing business as University of Colorado-Denver, $212,782 on September 9, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate developmental dysanapsis in lung development throughout the lifespan in experimental bronchopulmonary dysplasia. The research examines whether intra-amniotic endotoxin causes persistent dysanaptic growth of airways, distal parenchyma, and...
- The National Heart, Lung, and Blood Institute awarded Brown University $100,228 on December 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of chitinase 3-like-1 in pulmonary arterial hypertension pathogenesis. The project grant funds research into how the protein CHI3L1 contributes to immune and metabolic dysfunction underlying vascular remodeling in PAH, with particular focus on macrophage metabolism and pro-remodeling effects. The research...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of Colorado (University of Colorado-Denver) $1,357,964 on August 24, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to discover prognostic biomarkers of early pulmonary fibrosis and develop secondary prevention strategies. The research identifies genetic, molecular, and environmental biomarkers that trigger and predict progression of fibrotic interstitial lung abnormalities (FILAs)...
- The National Heart, Lung, and Blood Institute awarded the University of Maryland, Baltimore $775,687 under Project Grant R01HL183332 on August 10, 2026, to support research on molecular drivers of pulmonary vascular remodeling in pulmonary hypertension with heart failure and preserved ejection fraction (PH-HFPEF). The research investigates beta-2 microglobulin (B2M) as a therapeutic target in PH-HFPEF. The project builds on findings that PH-HFPEF patients display elevated circulating B2M...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $1,540,621 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate endothelial inflammation, C-terminal SRC kinase dysregulation, and fibrosis in early pulmonary arterial hypertension. The award funds research into molecular mechanisms regulating fibroproliferative pulmonary vascular remodeling in early PAH, with particular focus on patients with inflammatory...